Center for Cognitive and Memory Disorders

KatakiMariaAssistant Professor Clinical

College of Medicine
Department of Neurology

395 W. 12th Avenue
6th floor, R 618
Columbus, Ohio 43210
Phone: 614-293-4969
Email: maria.kataki@osumc.edu

Research Interests: Alzheimer’s disease and dementia, cognitive disorders in the spectrum of neurological and neuropsychiatric conditions; behavioral disturbances in the spectrum of dementias; mild cognitive impairment and early dementia; SAGE (Self-Administered Gerocognitive Examination); pharmacogenomics in dementia; functional imaging in dementia.

Research Techniques: Multi-site collaborative research studies for development of new medications for dementias; gene expression analysis; analysis of genetic polymorphisms; clinical studies; cognitive evaluation of patients to monitor early signs of a neurodegenerative process, progression and management over time; functional imaging biomarkers; CSF analysis; and volumetric MRI studies.

Active Funding:

  • Subinvestigator: A multicenter, randomized, double-blind, placebo-controlled, phase III study comparing solanezumab with placebo for 18 months in approximately 2,100 patients with mild Alzheimer’s disease. Elli Lilly and Company.
  • Subinvestigator: A randomized, double-blind, parallel-group, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; Study 1. Protocol 14861A. Sponsored by Lundbeck.
  • Subinvestigator: A randomized, double-blind, placebo-controlled, parallel-group, 26-week, phase III study of two doses of EVP-6124 or placebo in subjects with mild to moderate Alzheimer’s disease currently or previously receiving an acetyl cholinesterase inhibitor medication. Forum Pharmaceuticals.
  • Subinvestigator: A 24-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker, and pharmacokinetic study of AZD3293 in early Alzheimer’s disease (The AAMARANTH Study). Astra Zeneca.
  • Subinvestigator: A phase III, randomized, placebo-controlled, parallel-group, double-blind clinical trial to study the efficacy of MK-8931 (SCH 900931) in subjects with amnestic mild cognitive impairment due to Alzheimer’s disease (Prodromal AD). MK-8931-8931(SCH 900931). Merck Sharp & Dohme, Corp., a subsidiary of Merck & C0., Inc.
  • Subinvestigator: A seamless Phase IIa/IIb, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of MK-7622 as an adjunctive therapy to Donepezil for symptomatic treatment in subjects with Alzheimer’s disease. MK-7622. Meck Sharp & Dohme, Corp., a subsidiary of Merck & C0., Inc.
  • Subinvestigator: Protocol 14861B: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer’s disease. 14861B WIRB Protocol #20132100. H. Lundbeck A/S.
  • Subinvestigator: A 26-week extension study of safety and clinical effects of EVP-6124 in subjects with mild to moderate Alzheimer’s disease currently or previously receiving an acetyl cholinesterase inhibitor medication. Forum Pharmaceuticals

PubMed articles

Background: Dr. Maria Kataki graduated from National and Kapodistrian University of Athens, Medical School of Athens, Greece, and completed her first neurology residency and PhD in functional imaging at National University of Athens, Department of Neurology. Dr. Kataki completed her second neurology residency at the Baylor College of Medicine, Houston, Texas. Dr. Kataki completed her fellowship in Alzheimer’s disease and dementia at the Alzheimer’s Disease Research Center, Baylor College of Medicine. In 2004, she joined the faculty at The Ohio State University Department of Neurology, Neurobehavior Division, and she has served as the director of clinical operations of the Neurobehavior Division since 2014. Dr. Kataki is a board certified neurologist, with subspecialty training in Alzheimer’s disease and dementia, a clinical researcher, a physician’s educator and an expert in the field of cognitive disorders and neurodegenerative diseases.

Education:
MD, Medical School of Athens, National and Kapodistrian University of Athens, Greece, 1989
PhD, National and Kapodistrian University of Athens, Greece, Department of Neurology, 2003

Residencies:
Resident in Neurology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece
Intern, University of Texas-Houston Medical School, Houston, Texas
Resident in Neurology, Baylor College of Medicine, Houston, Texas

Fellowships:
Research Associate, Functional Neurosurgery, University of Texas, Health Science Center, Houston, Department of Neurosurgery
Fellow in Alzheimer’s Disease and Dementia, Baylor College of Medicine, Department of Neurology, and the Alzheimer’s Disease Research Center, Houston, Texas
Fellow in Neurobehavioral Neurology: Section of Neurobehavioral Neurology and the Houston VAMC Cognitive Disorders Center, Houston, Texas

Honors/News:

  • Visiting Resident, Department of Neurology, Alzheimer’s Disease Research Center, Baylor College of Medicine, Houston Texas, November 1993 - May 1994, sponsored by National university of Athens, Department of Neurology
  • Travel Award, 6th International Conference on Alzheimer’s Disease and Related Disorders. Amsterdam Rai 18-23 July 1998
  • Loren Rolak Award for 2003 for Best Online Case Publication in Neurology, Baylor College of Medicine, Department of Neurology
  • Who’s Who National Registry, 2004-2005
  • Who’s Who Madison Honorary Registry for Executive and Professionals, 2009-2011
  • Who’s Who Madison Honorary Registry for VIP Executive and Professionals 2009-2011
  • International Association of Health Care Professionals, “The Leading Physicians of the World,” Publication 2012-2013-2014 Recipient of the Neurosciences Excellence Award 2012, OSU Wexner Medical Center, Department of Neurology

My Clinical Bio

Share this Page